Purpose The population pharmacokinetics (PK) of lopinavir in tuberculosis (TB)/human immunodeficiency virus (HIV) co-infected South African children taking superboosted lopinavir (lopinavir/ritonavir ratio 1:1) as part of antiretroviral treatment in the presence of rifampicin were compared with the population PK of lopinavir in HIVinfected South African children taking standard doses of lopinavir/ritonavir (ratio 4:1). Methods Lopinavir concentrations were measured in 15 TB/HIV-co-infected paediatric patients who were sampled during and after rifampicin-based TB treatment and in 15 HIV-infected children without TB. During TB therapy, the dose of ritonavir was increased to lopinavir/ritonavir 1:1 in order to compensate for the induction of rifampicin. . Results Lopinavir oral clearance (CL/F) was about 30% lower in children without TB than in co-infected children treated with super-boosted lopinavir. However, the predicted lopinavir C min was above the recommended minimum therapeutic concentration during TB/HIV co-treatment in the 15 children. Lopinavir CL/F increased linearly during the dosing interval. Conclusions Increasing the ritonavir dose to achieve a lopinavir/ritonavir ratio of 1:1 when given in combination with rifampicin-based TB treatment did not completely compensate for the enhancement of lopinavir CL/F caused by rifampicin. The time-dependent lopinavir CL/F might be due to a time-dependent recovery from ritonavir inhibition of lopinavir metabolism during the dosing interval.
Introduction
Human immunodeficiency virus (HIV) and tuberculosis (TB) co-infection is a major problem in sub-Saharan Africa. In South Africa, about 50% of children with TB aged between 0 and12 years are HIV infected [1, 2] . Antiretroviral regimens including the lopinavir/ritonavir together with two nucleoside reverse transcriptase inhibitors (NRTIs) are commonly used in South African children. Lopinavir is a potent HIV protease inhibitor co-formulated with ritonavir at a ratio of 4:1. In this formulation, ritonavir acts as a booster of lopinavir concentrations due to its inhibitory effect on cytochrome P450 (CYP) enzyme 3A4 and P-glycoprotein, which are involved in lopinavir metabolism and transport [3] [4] [5] . TB/HIV-co-infected children should be treated with rifampicin for the whole TB treatment duration [6] . However, by inducing CYP3A4 and P-glycoprotein expression [7] [8] [9] , rifampicin reduces protease inhibitor concentrations to subtherapeutic concentrations [6, 10] . In adults, rifampicin reduces the area under the concentration-time curve (AUC) and the minimum concentration (C min ) of lopinavir by 75% and 99% respectively [11, 12] . Such a reduction can be overcome, in healthy adults, by administering extra ritonavir (super-boosted lopinavir with lopinavir/ritonavir at a 1:1 ratio) since it results in lopinavir C min similar to those obtained with a lopinavir/ ritonavir (4:1) regimen without rifampicin [12] . This approach needs to be validated in children with TB/HIV co-infection since the expression of CYP enzymes and P-glycoprotein as well as protein binding may be altered by age or disease [13, 14] . The population pharmacokinetics of lopinavir in children has been published before by for example Jullien et al. [15] and Rakhmanina et al. [16] . However, these models do not describe or take into account the pharmacokinetic interaction between lopinavir and rifampicin. Neither is the population pharmacokinetics described when given together with the booster ritonavir. The latter has been described previously [17, 18] , but not in children. As tuberculosis and HIV are very commonly co-existing in children in developing countries, it is a great need to develop population pharmacokinetic models in order to simulate and investigate optimal doses and dosing recommendations.
The aim of this analysis was to develop a model describing the dynamic PK interactions and comparing the population pharmacokinetics (PK) of lopinavir in TB/HIV-co-infected South African children taking lopinavir/ritonavir at a ratio of 1:1 in the presence of rifampicin treatment, to the population PK of lopinavir in HIV-infected South African children taking lopinavir/ritonavir at a ratio of 4:1.
Materials and methods

Study design
The data were available from a study consisting of two parallel treatment groups (Table 1) , TB/HIV co-infected children and children with HIV but not TB [19] . The TB/HIV co-infected children comprised 15 children (8 girls) aged from 7 to 34 months, weighing between 5 and13 kg with body surface area (BSA) measurements between 0. 28 
Data analysis
Lopinavir population PK were described using non-linear mixed effects modelling within NONMEM version VI (GloboMax, Austin, TX, USA) [20] . The typical population pharmacokinetic parameters, interindividual variability (IIV) and residual variability were estimated by the firstorder conditional estimation method with interaction.
One-and two-compartment models with first-order absorption were fitted to the data. Elimination was assumed to take place from the central compartment.
Interindividual variability was described using an exponential error model to avoid negative individual parameter estimates:
where Pi is the individual parameter, P is the typical parameter value and η I is the IIV that describes the difference between the typical parameter value and the individual estimate. The variable η I is normally distributed with mean 0 and variance ω 2 . Investigated residual error models were additive, proportional and slope-intercept models.
Model selection was achieved by the use of the objective function value (OFV), which is minus twice the log likelihood of the data. A drop in the OFV of 3.84 between the two nested models corresponding to p<0.05 was a Blood sampling for PK determination was done after a minimum of 4 weeks of treatment regarded as statistically significant. Graphical analysis using Xpose version 3.104 and version 4 [21] , standard error of the parameter estimates, and scientific plausibility were used for model selection as well. Covariate model building was performed by forwards inclusion and backwards deletion using an OFV change of > 10.83 (p<0.001) as the cut-off for inclusion, followed by stepwise deletion using an OFV change of > 12.12 (p<0.0001) to retain the effect on the selected parameters. Model validation was performed by bootstrap resampling [22] and a visual predictive check. In the bootstrap resampling, parameter estimates were re-estimated for each of 1,000 bootstrap samples. NONMEM estimates from the final model were compared with the bootstrap median and 95% confidence intervals. In the visual predictive check, the final model and parameter estimates were used to simulate 1,000 datasets based on the original design. Observed concentrations were compared with the simulated median and 95% non-parametric prediction interval.
Results
Lopinavir showed time-dependent oral clearance (CL/F) in all children. Lopinavir CL/F increased linearly during the dosing interval. Ritonavir inhibits CYP3A4 and hence the elimination of lopinavir [3] . Recovery from ritonavir inhibition during the dosing interval was described with a rate constant k r . The final model for lopinavir oral clearance (CL/F) was:
where (CL/F) 0 is lopinavir CL/F at the beginning of the dosing interval and TAD is the time after dose in hours. Table 2 . None of the PK parameters was related to age, weight or gender.
The median sampling time (range) for the nominal 12-h sample was 11.58 (10.50-12.07), 11.50 (9.25-12.00) and 12.00 (11.55-12.42) h after dose administration in the children during and after TB treatment, and in those without TB respectively. Due to the aforementioned wide ranges of the actual sampling time for the last sample, the nominal 12-h sample, lopinavir concentrations were predicted at 11.9 h after dose administration. Model predicted lopinavir concentrations, for all individuals, were above the recommended minimum therapeutic concentration (1 mg/L) [23] . The bootstrap validation results showing the medians and the 95% confidence intervals for 1,000 bootstrap samples are represented in Table 2 . Figure 1 shows visual predictive check plots obtained from simulation of 1,000 datasets based on the final model. Figure 2 shows plots of observed and individual predicted lopinavir concentration in children with poor, typical and best goodness-of-fit, categorised by the average of the absolute values of the weighted individual residuals.
Discussion
Increasing the dose of ritonavir to achieve a lopinavir/ ritonavir ratio of 1:1did not completely counteract the induction of lopinavir metabolism by rifampicin in this study as lopinavir CL/F was modestly higher during TB treatment than it was after TB treatment completion. Although giving larger doses of ritonavir may, in theory, fully compensate for the effect of rifampicin on lopinavir CL/F, this needs to be evaluated in patients. When ritonavir was taken in therapeutic doses to act as an HIV protease inhibitor, it induced CYP3A4 [24] [25] [26] and, in vitro, ritonavir activates the pregnane X receptor, although it decreases microsomal CYP3A4 activity due to irreversible enzyme inhibition [27] .
Even after TB treatment, CL/F in the co-infected children was greater than in children without TB, indicating increased CL or reduced bioavailability of lopinavir, or both, in the TB/HIV co-infected group. This could be attributed to a disease effect, or sampling bias as the study was small. Lopinavir V/F was 2-fold larger in children with TB/HIV compared with children without TB. Lopinavir is 98-99% bound to plasma proteins, mainly alpha-1-acid glycoprotein and albumin [4] . The larger V/F in the co-infected children might be attributed to lower albumin concentrations compared with children without TB [28, 29] , or to reduced bioavailability of lopinavir since the same trend was found in CL/F.
In healthy adults, administering extra ritonavir (lopinavir/ritonavir 1:1) resulted in a similar lopinavir maximum concentration and AUC to those obtained with the standard lopinavir/ritonavir (4:1) regimen without rifampicin [12] . The inability of the extra ritonavir dose to completely counteract rifampicin induction of lopinavir CL/F in this study may be due to the higher hepatic enzymatic activity in children between 1 and 4 years compared with adults [13] . However, the clinically relevant criterion for monitor- ing virological efficacy is the trough sample at 12 h after the dose for drugs given twice daily [23] . The C min predicted by the model suggest that administering extra ritonavir (lopinavir/ritonavir 1:1) is sufficient to maintain the C min above 1 mg/L in the children studied. However, this dosing regimen needs further evaluation in a larger population of children. It is important to note that the BSAderived doses of lopinavir/ritonavir and ritonavir were rounded up to the nearest 0.5 mL of the oral solutions, such that the doses/BSA of lopinavir and ritonavir respectively were 27% and 31% greater than 230 mg/m 2 during TB treatment.
Lopinavir showed time-dependent PK where its CL/F increased linearly during the 12-h dosing interval, probably because of recovery from inhibition by ritonavir. The recovery rate constant, k r , was 0.0582 h -1 in the coinfected children during TB treatment, while after TB treatment and in children without TB, k r was 0.0648 h -1 . The estimated k r values correspond to longer half-life values than those reported for ritonavir [30, 31] , indicating that enzymatic inhibition by ritonavir is mechanism-based and not only competitive. Assuming mechanism-based inhibition and that the half-life of the inhibitor is negligible in comparison to the turnover half-life of the enzyme, the rate constant for recovery from inhibition corresponds to the rate constant of enzyme turnover [32] . The lower k r during TB treatment, in comparison to that after TB treatment and children without TB, may be due to the fact that patients with TB/HIV co-infection have lower protein anabolism than patients with HIV infection alone [28] . Recovery from ritonavir inhibition of CYP3A4 in adults is nearly complete 3 days after discontinuation [33] . Our estimated recovery half-life was 11.9 h during TB treatment and 10.7 h after TB treatment and in the group without TB. This means that 3 days after discontinuation of ritonavir, the recovery in the co-infected children during TB treatment would be 98% whilst after TB treatment and in the children without TB it would be 99%. A previous attempt to link lopinavir population PK to ritonavir exposure resulted in a time-independent inverse relationship between lopinavir CL/F and exposure to ritonavir [3] . However, since ritonavir plasma concentrations were not available from our study, there was no relationship between lopinavir PK and ritonavir PK in the model.
Non-compartmental analysis of the data showed a nonsignificant trend for lopinavir half-life (t 1/2 ) to be larger in the co-infected children during TB treatment compared with the children without TB [19] . This is consistent with the estimated population pharmacokinetic parameters, since lopinavir t 1/2 at the beginning of the dosing interval and Fig. 2 Observed (open circles) and individual predicted (solid lines) lopinavir concentration-time curves from the final lopinavir pharmacokinetic model in a the TB/HIV group during TB treatment, b the TB/HIV group after TB treatment and c the HIV group. "Poor", "Typical" and "Best" denote the goodness-of-fit, categorised by the average of the absolute values of the weighted individual residuals 12 h after the dose respectively were 11.5 h and 6.77 h for the co-infected children during TB treatment compared with 7.98 h and 4.49 h in children without TB.
Our study may have been too small to detect any effects of age or sex within the 6-month to 4-year age range of the study. Very young children (≤6 months) require increased doses/BSA of lopinavir/ritonavir in order to achieve the same lopinavir concentrations as those in older children and adults [15, 32, 34] , and a 39% increase in CL/F has been reported for boys compared with girls in children older than 12 years [35] .
In conclusion, our study suggests that super-boosted lopinavir (lopinavir/ritonavir at a ratio of 1:1) in children treated concomitantly with rifampicin-based TB treatment results in therapeutic concentrations of lopinavir (C min > 1 mg/L). However, larger studies including younger and older children are needed to evaluate the pharmacokinetics, safety and efficacy of the combination of lopinavir, ritonavir and rifampicin in children. Lopinavir PK was time-dependent, probably due to recovery from ritonavir inhibition of lopinavir metabolism during the dosing interval.
